Posted by Michael Wonder on 11 Oct 2019
Another treatment option for ovarian cancer approved for the Cancer Drugs Fund
11 October 2019 - An ovarian cancer treatment, designed to help maintain the effects of chemotherapy, has been approved by NICE for use in the Cancer Drugs Fund.
Rucaparib can now be offered to women with relapsed ovarian, fallopian tube or peritoneal cancer, that has responded to platinum-based chemotherapy. Taken as a tablet, twice daily, it slows the progression of cancer by preventing cancer cells repairing so slowing down the tumour’s growth.
Around 1,350 people in England could benefit from this new treatment which will be available immediately through the Cancer Drugs Fund.
